Bio-Rad Laboratories (BIO) reported Q4 adjusted net income late Thursday of $2.90 per diluted share, down from $3.10 a year ago.
Analysts polled by FactSet expected $2.87.
Revenue for the quarter that ended Dec. 31 was $667.5, down from $681.2 million a year ago.
Analysts surveyed by FactSet expected $679.3 million.
For 2025, the company expects non-GAAP, currency-neutral revenue growth of 1.5% to 3.5% and non-GAAP operating margin of 13.0% to 13.5%.
Bio-Rad shares were down about 4% in extended trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。